| scholarly article | Q13442814 |
| P50 | author | Margherita Macera | Q92193504 |
| Salvatore Martini | Q123357978 | ||
| Mariantonietta Pisaturo | Q56855268 | ||
| Rosa Zampino | Q59158585 | ||
| Evangelista Sagnelli | Q41549310 | ||
| Caterina Sagnelli | Q42257713 | ||
| P2093 | author name string | Nicola Coppola | |
| Giuseppe Pasquale | |||
| P2860 | cites work | FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C | Q79671109 |
| Liver cirrhosis: evaluation of haemodynamic changes using an ultrasound contrast agent | Q80178752 | ||
| Fibrosis is worse in HIV-HCV patients with low-level immunodepression referred for HCV treatment than in HCV-matched patients | Q80518524 | ||
| Liver biopsy | Q83395480 | ||
| Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease | Q87406034 | ||
| Cirrhosis: diagnosis with sonographic study of the liver surface | Q93514132 | ||
| Emerging concepts in the immunopathogenesis of AIDS | Q22241984 | ||
| Microbial translocation is a cause of systemic immune activation in chronic HIV infection | Q22251054 | ||
| Senescence of activated stellate cells limits liver fibrosis | Q24621822 | ||
| Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes | Q27488883 | ||
| Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers | Q28258678 | ||
| Human immunodeficiency virus and liver disease forum 2010: conference proceedings | Q28674930 | ||
| Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups | Q29614459 | ||
| An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group | Q29614898 | ||
| TLR4 enhances TGF-beta signaling and hepatic fibrosis | Q29620016 | ||
| Acoustic Radiation Force Impulse (ARFI) and Transient Elastography (TE) for evaluation of liver fibrosis in HIV-HCV co-infected patients | Q30426477 | ||
| Sampling variability of liver fibrosis in chronic hepatitis C. | Q48583601 | ||
| Prognosis of chronic hepatitis C: results of a large, prospective cohort study. | Q50856021 | ||
| Impaired CD4⁺ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. | Q51001604 | ||
| Comparison of surrogate serum markers and transient elastography (Fibroscan) for assessing cirrhosis in patients with chronic viral hepatitis. | Q51701375 | ||
| Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. | Q51717108 | ||
| Serum markers detect the presence of liver fibrosis: a cohort study. | Q51983072 | ||
| Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. | Q51993308 | ||
| Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. | Q52274671 | ||
| Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis | Q57782884 | ||
| Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: A pilot study | Q57818202 | ||
| Evaluation of an aspiration-type semiautomatic cutting biopsy needle | Q58212988 | ||
| Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population | Q58622626 | ||
| Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection | Q60164336 | ||
| Transjugular Liver Biopsy | Q60188752 | ||
| Similar Success Rates but Lower Incidence of Telaprevir-Related Rash in HIV/HCV Coinfected as Compared to HCV-Monoinfected Patients Treated With Triple Anti-HCV Therapy | Q60621766 | ||
| The role of liver biopsy in chronic hepatitis C | Q61698877 | ||
| Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation | Q61895904 | ||
| The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD | Q61989968 | ||
| FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest | Q62658359 | ||
| Type III procollagen peptide: a marker of disease activity and prognosis in primary biliary cirrhosis | Q69917807 | ||
| Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies | Q70032258 | ||
| Tissue inhibitor of metalloproteinase is increased in the serum of precirrhotic and cirrhotic alcoholic patients and can serve as a marker of fibrosis | Q72430996 | ||
| Ultrasound-guided liver biopsy for parenchymal liver disease: an economic analysis | Q74331017 | ||
| Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients | Q45421063 | ||
| BHIVA guidelines: coinfection with HIV and chronic hepatitis C virus | Q45711099 | ||
| Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis | Q45736423 | ||
| Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study | Q45737816 | ||
| Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group | Q45747079 | ||
| Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group | Q46225118 | ||
| Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. | Q46450252 | ||
| Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index | Q46490993 | ||
| Different hemodynamic patterns of alcoholic and viral endstage cirrhosis: analysis of explanted liver weight, degree of fibrosis and splanchnic Doppler parameters. | Q47299129 | ||
| Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. | Q47876312 | ||
| Glutathione deficiency is associated with impaired survival in HIV disease | Q30454442 | ||
| Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C | Q30463023 | ||
| Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population | Q30471258 | ||
| Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity | Q32061742 | ||
| Meta-analyses of FibroTest diagnostic value in chronic liver disease | Q33302708 | ||
| Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy | Q33422417 | ||
| Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients | Q33502234 | ||
| Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? | Q33665359 | ||
| The feasibility and reliability of transient elastography using Fibroscan®: a practice audit of 2335 examinations | Q33810066 | ||
| Molecular mechanisms of liver fibrosis in HIV/HCV coinfection | Q33907429 | ||
| Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection | Q34154927 | ||
| EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q34168383 | ||
| Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers | Q34209648 | ||
| Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia | Q34301709 | ||
| Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland | Q34352028 | ||
| Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. | Q34359330 | ||
| Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. | Q34390093 | ||
| Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. | Q34437952 | ||
| Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection | Q34438649 | ||
| Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease | Q34605692 | ||
| Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension | Q34631908 | ||
| HIV infection increases HCV-induced hepatocyte apoptosis | Q34699457 | ||
| Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review | Q34754575 | ||
| Diagnosis and quantitation of fibrosis | Q34777918 | ||
| Hepatitis C and HIV co-infection: a review | Q34782891 | ||
| HCV and HIV co-infection: mechanisms and management. | Q35090634 | ||
| Coinfection with HIV-1 and HCV--a one-two punch | Q35137038 | ||
| CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis | Q35847699 | ||
| Assessment of liver fibrosis in co-infected patients | Q36341019 | ||
| HIV/HCV co-infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article | Q36820091 | ||
| Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis | Q37073732 | ||
| Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination | Q37128257 | ||
| Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection | Q37202576 | ||
| Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience | Q37552675 | ||
| Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs | Q37619741 | ||
| Coinfection by human immunodeficiency virus and hepatitis C virus: noninvasive assessment and staging of fibrosis | Q38022504 | ||
| Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. | Q38070696 | ||
| The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis | Q38117079 | ||
| Treatment of chronic hepatitis C in patients with HIV/HCV coinfection | Q38352572 | ||
| Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease. | Q38879814 | ||
| Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients. | Q39018310 | ||
| Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting | Q39096729 | ||
| Hepatitis C and Human Immunodeficiency Virus Envelope Proteins Cooperatively Induce Hepatocytic Apoptosis via an Innocent Bystander Mechanism | Q39281648 | ||
| Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner | Q39938266 | ||
| HIV increases HCV replication in a TGF-beta1-dependent manner. | Q40004969 | ||
| Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults | Q40142710 | ||
| Chronic hepatitis: morphology and nomenclature. | Q40649870 | ||
| Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients | Q40850644 | ||
| Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients | Q42222997 | ||
| Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection | Q42255783 | ||
| Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration | Q42272013 | ||
| Serum levels of tissue inhibitor of metalloproteinase-1 are correlated with liver fibrosis in patients with chronic hepatitis B. | Q42288534 | ||
| Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. | Q42923153 | ||
| Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy. | Q42977009 | ||
| Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial | Q42980412 | ||
| HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection | Q42986755 | ||
| Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus | Q42996446 | ||
| Immunological status does not influence hepatitis c virus or liver fibrosis in HIV-hepatitis C virus-coinfected patients | Q43000875 | ||
| Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection | Q43056741 | ||
| Liver histology in HIV/hepatitis C-coinfected and HCV-monoinfected patients with persistently normal alanine aminotransferases | Q43085980 | ||
| Strong correlation by ultrasonography of hepatomegaly and the presence of co-infection in HIV/HCV cirrhotic patients | Q43450176 | ||
| Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy | Q43693273 | ||
| European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. | Q43747979 | ||
| Liver biopsy in chronic hepatitis C: the experience of 15 Italian wards of infectious diseases. | Q43816873 | ||
| Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease | Q44290461 | ||
| Severe liver fibrosis or cirrhosis: accuracy of US for detection--analysis of 300 cases | Q44324874 | ||
| Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. | Q44520884 | ||
| Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease | Q44539715 | ||
| HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension | Q44561456 | ||
| The long-term pathological evolution of chronic hepatitis C. | Q44765507 | ||
| Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection | Q44920531 | ||
| Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis | Q44966935 | ||
| Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study | Q45397541 | ||
| Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma | Q45402508 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis C virus | Q708693 |
| coinfection | Q1243018 | ||
| P304 | page(s) | 2510-2521 | |
| P577 | publication date | 2015-10-01 | |
| P1433 | published in | World Journal of Hepatology | Q27723328 |
| P1476 | title | Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact | |
| P478 | volume | 7 |
| Q40113130 | Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients |
| Q49727776 | Current characteristics of hemophilia patients co-infected with HIV/HCV in Japan. |
| Q47554912 | Factors associated with urinary tract infections among HIV-1 infected patients |
| Q46016322 | Inflammation and Fibrosis in HIV: Getting to the Heart of the Matter. |
| Q38606313 | Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection |
| Q40482870 | TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype. |
| Q38753617 | Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era. |
Search more.